In last trading session, Sangamo Therapeutics Inc (NASDAQ:SGMO) saw 5.75 million shares changing hands with its beta currently measuring 1.40. Company’s recent per share price level of $0.92 trading at -$0.08 or -7.28% at ring of the bell on the day assigns it a market valuation of $192.74M. That closing price of SGMO’s stock is at a discount of -245.65% from its 52-week high price of $3.18 and is indicating a premium of 67.39% from its 52-week low price of $0.30. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 4.47 million shares which gives us an average trading volume of 6.52 million if we extend that period to 3-months.
For Sangamo Therapeutics Inc (SGMO), analysts’ consensus is at an average recommendation of Hold while assigning it a mean rating of 1.88. Splitting up the data highlights that, out of 3 analysts covering the stock, 0 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 2 suggested the stock as a Hold whereas 1 see the stock as a Buy. 0 analyst(s) advised it as an Underweight.
Sangamo Therapeutics Inc (NASDAQ:SGMO) trade information
Upright in the red during last session for losing -7.28%, in the last five days SGMO remained trading in the red while hitting it’s week-highest on Friday, 03/07/25 when the stock touched $0.92 price level, adding 13.21% to its value on the day. Sangamo Therapeutics Inc’s shares saw a change of -9.43% in year-to-date performance and have moved -7.62% in past 5-day. Sangamo Therapeutics Inc (NASDAQ:SGMO) showed a performance of -18.96% in past 30-days. Number of shares sold short was 26.5 million shares which calculate 7.0 days to cover the short interests.
Wall Street analysts have assigned a consensus price target of 2.5 to the stock, which implies a rise of 63.2% to its current value. Analysts have been projecting 2 as a low price target for the stock while placing it at a high target of 3. It follows that stock’s current price would drop -117.39% in reaching the projected high whereas dropping to the targeted low would mean a loss of -117.39% for stock’s current value.
Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of -15.96% during past 5 years. In 2025, company’s earnings growth rate is likely to be around 68.41% while estimates for its earnings growth in next 5 years are of 42.22%.
Sangamo Therapeutics Inc (NASDAQ:SGMO)’s Major holders
Insiders are in possession of 2.33% of company’s total shares while institution are holding 29.59 percent of that, with stock having share float percentage of 30.30%. Investors also watch the number of corporate investors in a company very closely, which is 29.59% institutions for Sangamo Therapeutics Inc that are currently holding shares of the company. WASATCH ADVISORS LP is the top institutional holder at SGMO for having 20.09 million shares of worth $7.2 million. And as of 2024-06-30, it was holding 9.8509 of the company’s outstanding shares.
The second largest institutional holder is ARMISTICE CAPITAL, LLC, which was holding about 14.06 million shares on 2024-06-30. The number of shares represents firm’s hold over 6.894 of outstanding shares, having a total worth of $5.04 million.
On the other hand, Wasatch Ultra Growth Fund and Vanguard Total Stock Market Index Fund are the top two Mutual Funds which own company’s shares. As of Dec 31, 2024 , the former fund manager was holding 5.79 shares of worth $5.35 million or 2.78% of the total outstanding shares. The later fund manager was in possession of 5.65 shares on Dec 31, 2024 , making its stake of worth around $5.22 million in the company or a holder of 2.71% of company’s stock.
